對照品 > 標準品 > 美國藥典 >
產(chǎn)品基本信息
產(chǎn)品編號：S870002
產(chǎn)品名稱：Suvorexant-d6
產(chǎn)品CAS：
規(guī)格含量：25mg
產(chǎn)品價格：面議
聯(lián)系我們:
產(chǎn)品詳細介紹
標準品編號:
S870002
名稱:
Suvorexant-d6
別名:
[(7R)-4-(5-Chloro-2-benzoxazolyl)hexahydro-7-methyl-1H-1,4-diazepin-1-yl][5-methyl-d3-2-(2H-1,2,3-triazol-2-yl)phenyl-d3]-methanone; 5-Chloro-2-[(5R)-5-methyl-4-[5-methyl-d3-2-(2H-1,2,3-triazol-2-yl)benzoyl-d3]-1,4-diazepan-1-yl]-1,3-benzoxazole; MK 4305-d6; [(R)-4-(5-Chloro-benzooxazol-2-yl)-7-methyl-[1,4]diazepan-1-yl]-(5-methyl-d3-2-[1,2,3]triazol-2-yl-phenyl-d3)-methanone
參考CAS號:
類似: 1030377-33-3
分子式:
C??H??D?ClN?O?
分子量:
456.96
類別:
Building Blocks; Isotopic Labeled Analogues;
應用:
Suvorexant-d6 is the labeled analog of Suvorexant (S870000), a dual (non-selective) orexin receptor antagonist in development by Merck & Co. for the treatment of insomnia. It works by turning off wakefulness rather than by inducing sleep. Users of higher doses had an increased rate of suicidal ideation.
參考文獻
Cox, C., et al.: J. Med. Chem., 53, 5320 (2010); Baxter, C., et al.: Org. Process Res. Dev., 15, 367 (2011); Winrow, C., et al.: J. Neurogenet., 25, 52 (2011); Mieda, M., et al.: CNS Drugs, 27, 83 (2013); Osborne, R.: Nat. Rev. Drug Discov., 12, 492 (2013)
?您的位置：
